Key result
The efficacy and safety of direct oral anticoagulants for the prevention of stroke or systemic embolism in patients with bioprosthetic valves and atrial fibrillation remains uncertain.
Why the study?
Data guiding the most effective anticoagulation strategy in patients with a bioprosthetic heart valve and AF are limited, and the use of DOACs for stroke or systemic embolism prevention in this population remains uncertain.
Do direct oral anticoagulants (DOACs) prevent stroke or systemic embolism in patients with a bioprosthetic heart valve and concomitant atrial fibrillation (AF)?
Do direct oral anticoagulants (DOACs) prevent stroke or systemic embolism in patients with a bioprosthetic heart valve and concomitant atrial fibrillation (AF)?
The efficacy and safety of DOACs for stroke prevention in patients with bioprosthetic heart valves and atrial fibrillation remains uncertain compared to vitamin-K antagonists.
Supports DOACs as alternative to VKA in bioprosthetic valve AF; extends evidence from nonvalvular AF trials.
There are limited data to guide the most effective anticoagulation strategy in patients with a bioprosthetic heart valve and concomitant atrial fibrillation (AF). The use of vitamin-K antagonists (VKA) has been supported by limited data from randomized trials.1 Direct oral anticoagulants (DOACs) have emerged as an effective and safe alternative to VKA and are now considered the preferred agents for stroke prevention in most patients with non-valvular AF. However, the use of DOACs for the prevention of stroke or systemic embolism in patients with bioprosthetic valve and AF remains uncertain.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2021) conducted a review in Atrial fibrillation and bioprosthetic heart valves. Direct oral anticoagulants (DOACs) vs. Vitamin-K antagonists (VKA) was evaluated on Stroke or systemic embolism. The efficacy and safety of direct oral anticoagulants for the prevention of stroke or systemic embolism in patients with bioprosthetic valves and atrial fibrillation remains uncertain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: